ImmuPharma (LON:IMM) Trading Up 9.5% - Time to Buy?

Key Points

• ImmuPharma's stock saw a significant increase of 9.5% during mid-day trading, with a last traded price of GBX 12.10 ($0.16).
• The company has a market capitalization of £60.47 million, a PE ratio of -1,359.55, and a beta of 1.53, indicating high volatility.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program Lupuzor™ showing promise in treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was up 9.5% during mid-day trading on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). Approximately 23,646,498 shares traded hands during trading, an increase of 176% from the average daily volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Stock Performance

The firm has a market capitalization of £60.47 million, a PE ratio of -1,359.55 and a beta of 1.53. The firm's 50-day moving average is GBX 4.46 and its 200 day moving average is GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.